A synthesis of randomized ICU trials found different advantages across outcomes rather than a universally superior sedative.
Fifteen trials compared midazolam with dexmedetomidine in mechanically ventilated adults. The review reported shorter ventilation and lower delirium risk with dexmedetomidine, alongside more bradycardia. ICU length of stay and all-cause mortality did not differ significantly in the pooled analyses.
Ventilation outcomes were heterogeneous, and sedation targets, doses, mobilization, and extubation practices differed. A nonsignificant mortality result is not proof of identical mortality risk. Group-level differences cannot establish the counterfactual outcome of one patient.
For an ICU opinion, specify the endpoint and cardiovascular context. A delirium benefit should not erase a heart-rate tradeoff, and a favorable average ventilation result is not an individual guarantee. The full regimen, target sedation depth, clinical course, and reasons for agent selection remain important.
Source reviewed: Efficacy and safety of midazolam versus dexmedetomidine in mechanically ventilated intensive care un (PMC12891203). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Volatile-Anesthetic Comparison Found a Nausea Signal Without an Analgesic Advantage; Neonatal Seizure Control Was Assessed Clinically Without EEG in a Midazolam Comparison.